EGFR and cancer: For example, targeting of Epidermal Growth Factor Receptor (EGFR) with small molecules or monoclonal antibodies has been reported to offer no survival benefit [1], despite the fact that EGFR is the most common genomically altered oncogene in GBM, and targeting EGFR has shown benefit in other cancers.